



Q1 2009 turnover
Sustained growth and a solid cash situation
Significant portfolio developments

Paris, April 29, 2009 – BioAlliance Pharma SA (Euronext Paris – BIO), the specialty pharmaceutical company focused on the treatment of opportunistic infections in cancer and AIDS, today announced a consolidated turnover of €2.6 million for Q1 2009.

Revenues

Loramyc[®] sales totaled €0.4 million, reflecting the product's sustained commercial success. Almost 7000 patients were treated during Q1 2009, versus 2200 in Q1 2008.

"2009 has started well for our first product", stated Dominique Costantini, Chairman of BioAlliance Pharma's Executive Board. "The increasing adoption of Loramyc[®] as the preferred treatment for oropharyngeal candidiasis by hospital-based specialists is being confirmed month after month. This is a key factor, given that we are continuing our discussions with potential European partners in the field of cancer supportive care".

Revenue from agreements and licenses for Q1 2009 represented €2.2 million, versus €3.7 million for the same period in 2008. This variation is due to the fact that non-recurrent payments received are spread out in the accounts. Notably, over Q1 2009 a €1.2 million residual amount regarding the SpeBio agreement has been recognized as revenues after BioAlliance Pharma reacquired the sales rights to Loramyc[®] in Europe.

Cash and cash equivalents

The company's cash reserves amounted to €27 million as of March 31, 2009. This sum includes the reimbursement of research tax credits for the period 2004-2007 (€2.4 million). An additional €2.2 million (corresponding to the research tax credit for 2008) was received in April 2009.

Two key events are going to reinforce BioAlliance Pharma's cash position:

- under the terms of existing Loramyc[®] licensing contracts in the United States and Asia, the company is due to receive \$21.5 million in milestone payments over the period 2009-2010;
- in Q1 2009, BioAlliance Pharma obtained €6.4 million in funding from OSEO (the French state innovation agency). From 2009 onwards, these funds will be devoted to two promising development programs (AMEP[™] and Zyxine) in the field of invasive tumors.

In all, the company has enough cash and cash equivalents to fund its operating activity over the next two years. This forecast does not include potential commercialization agreements on Loramyc[®] or other portfolio products.

State of development of the company's portfolio during the first half of 2009

- A European filing for Ondansetron RapidFilm™.
- Recovery of the European rights to Loramyc®, following termination of the agreement with SpePharm/SpeBio. BioAlliance Pharma has initiated legal procedures before the relevant courts in order to obtain compensation for losses and damages suffered.
- Loramyc® granted product marketing authorization in Korea (Handok license).
- Manufacturing file for Loramyc® in the USA to be completed by introduction of a debossed tablet.
- Presentations at major scientific congresses on AIDS and cancer (CROI and AACR), marking progress in three promising programs: a new HIV integrase inhibitor, oral irinotecan in colon cancer and the AMEP™ biotherapy in metastatic melanoma.

About BioAlliance Pharma

As a preferred partner for hospital-based specialists, BioAlliance Pharma is a specialty biopharmaceutical company which develops and markets innovative products, especially in the fields of opportunistic infections and chemotherapy complications. In areas where medical needs are insufficiently met, our targeted approaches help overcome drug resistance and improve patient health & quality of life. BioAlliance Pharma's ambition is to become a leading player in these fields by coupling innovation to patient needs.

For more information, visit the BioAlliance Pharma web site at <http://www.bioalliancepharma.com>.

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioAlliance Pharma SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the 2008 Reference Document filed with the AMF on April 7, 2009, which is available on the AMF website (<http://www.amf-france.org>) or on BioAlliance Pharma S.A.'s website (<http://www.bioalliancepharma.com>).

BioAlliance Pharma SA

Dominique Costantini, President and CEO

Tel.: +33 1 45 58 76 01

dominique.costantini@bioalliancepharma.com

Nicolas Fellmann, CFO

Tel.: +33 1 45 58 71 00

nicolas.fellmann@bioalliancepharma.com

ALIZE RP

Caroline Carmagnol

Tel.: +33 6 64 18 99 59

caroline@alizerp.com